I
0.734
0.01 (0.94%)
| Previous Close | 0.727 |
| Open | 0.746 |
| Volume | 385,996 |
| Avg. Volume (3M) | 3,726,118 |
| Market Cap | 52,810,452 |
| Price / Book | 2.54 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 |
| Diluted EPS (TTM) | -1.49 |
| Total Debt/Equity (MRQ) | 6.67% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -80.49 M |
| Levered Free Cash Flow (TTM) | -45.58 M |
| Return on Assets (TTM) | -70.13% |
| Return on Equity (TTM) | -138.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | IO Biotech, Inc. | Mixed | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | 0.13 |
Select this tab to load the latest available analysis.
|
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 66.43% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |